BR0214582A - Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma - Google Patents

Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma

Info

Publication number
BR0214582A
BR0214582A BR0214582-0A BR0214582A BR0214582A BR 0214582 A BR0214582 A BR 0214582A BR 0214582 A BR0214582 A BR 0214582A BR 0214582 A BR0214582 A BR 0214582A
Authority
BR
Brazil
Prior art keywords
ccr
asthma
treatment
piperazine derivatives
receptor antagonist
Prior art date
Application number
BR0214582-0A
Other languages
English (en)
Inventor
Daisy Joe Du Bois
Denis John Kertesz
Eric Brian Sjogren
David Bernard Smith
Beihan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0214582A publication Critical patent/BR0214582A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

"DERIVADOS DE PIPERAZINA PARA USO COMO ANTAGONISTAS DO RECEPTOR CCR-3 NO TRATAMENTO DE ASMA". A presente invenção refere-se a derivados de piperazina da Fórmula (I) em que: R^ 1^-R^ 4^, A, L e x são conforme definidos no relatório descritivo. Os compostos são úteis como antagonistas do receptor CCR-3 e, portanto, podem ser usados para o tratamento de doenças mediadas pelo CCR-3, tal como asma.
BR0214582-0A 2001-11-30 2002-11-25 Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma BR0214582A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33465501P 2001-11-30 2001-11-30
PCT/EP2002/013217 WO2003045393A1 (en) 2001-11-30 2002-11-25 Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma

Publications (1)

Publication Number Publication Date
BR0214582A true BR0214582A (pt) 2004-11-03

Family

ID=23308174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214582-0A BR0214582A (pt) 2001-11-30 2002-11-25 Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma

Country Status (16)

Country Link
US (1) US6906073B2 (pt)
EP (1) EP1453514B1 (pt)
JP (1) JP2005516903A (pt)
KR (1) KR100586131B1 (pt)
CN (1) CN1321115C (pt)
AR (1) AR037459A1 (pt)
AT (1) ATE367160T1 (pt)
AU (1) AU2002352122A1 (pt)
BR (1) BR0214582A (pt)
CA (1) CA2467966A1 (pt)
DE (1) DE60221275T2 (pt)
ES (1) ES2290346T3 (pt)
MX (1) MXPA04004981A (pt)
PL (1) PL370746A1 (pt)
RU (1) RU2004120063A (pt)
WO (1) WO2003045393A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235855A1 (en) * 2003-03-31 2004-11-25 Bharat Lagu Phospholipase C inhibitors for use in treating inflammatory disorders
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
CA2531167C (en) 2003-06-30 2012-05-22 Sumitomo Chemical Company, Limited Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
WO2005113513A2 (en) * 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
WO2007005214A1 (en) * 2005-06-29 2007-01-11 Janssen Pharmaceutica, N.V. Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds
EP1948629A1 (en) * 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US8338426B2 (en) * 2007-07-03 2012-12-25 Janssen Pharmaceutica Nv Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor
AU2009285591B2 (en) * 2008-08-29 2015-08-27 Treventis Corporation Compositions and methods of treating amyloid disease
PE20150925A1 (es) * 2009-04-22 2015-06-14 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida
PE20150759A1 (es) * 2009-04-22 2015-05-15 Axikin Pharmaceuticals Inc Antagonistas ccr3 arilsulfonamida
AU2018244211B2 (en) * 2017-03-26 2022-05-12 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
EP3821947A1 (en) * 2019-11-13 2021-05-19 Libra Therapeutics, Inc. Heterocyclic trpml1 agonists
TW202136219A (zh) * 2019-12-19 2021-10-01 美商卡司馬療法公司 Trpml調節劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592921A (ja) 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6455528B1 (en) * 1997-10-14 2002-09-24 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
JP2002179651A (ja) * 1998-06-19 2002-06-26 Wakamoto Pharmaceut Co Ltd ベンズアニリド誘導体及び医薬組成物
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2346933A1 (en) 1998-12-18 2000-06-22 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BR9917038A (pt) 1998-12-18 2002-04-02 Du Pont Pharm Co Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69926919D1 (de) 1998-12-18 2005-09-29 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren

Also Published As

Publication number Publication date
AR037459A1 (es) 2004-11-10
CN1321115C (zh) 2007-06-13
ES2290346T3 (es) 2008-02-16
ATE367160T1 (de) 2007-08-15
EP1453514B1 (en) 2007-07-18
KR100586131B1 (ko) 2006-06-07
CA2467966A1 (en) 2003-06-05
PL370746A1 (en) 2005-05-30
WO2003045393A1 (en) 2003-06-05
DE60221275T2 (de) 2008-05-08
RU2004120063A (ru) 2005-06-10
AU2002352122A1 (en) 2003-06-10
EP1453514A1 (en) 2004-09-08
KR20040065570A (ko) 2004-07-22
US20030176441A1 (en) 2003-09-18
DE60221275D1 (de) 2007-08-30
CN1599611A (zh) 2005-03-23
US6906073B2 (en) 2005-06-14
MXPA04004981A (es) 2004-08-11
JP2005516903A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
BR0208192A (pt) Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7.
MY137535A (en) New pyrrolidinium derivatives
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0214582A (pt) Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma
AU2003242544A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
IS6520A (is) Ný efnasambönd
MY132106A (en) New pyridazin-3(2h)-one derivatives
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
BR9915210A (pt) N-aril-amidas de ácido antranìlico-e ácido tioantranìlico
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
SE9904738D0 (sv) Novel compounds
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
GB0112348D0 (en) Compounds
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
BR0306922A (pt) N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina
BRPI0315644B8 (pt) compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
BRPI0407841A (pt) inibidores heterocìclicos de quinase
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
AU2003226765A1 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
ATE274515T1 (de) Pyrazolopyridinderivate

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.